Clinical Trials

Clinical Trial Detail

Return to search results.

A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "BIRCH"

Complete title: A Phase II, Multicenter, Single-Arm study of MPDL3280A in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell lung Cancer

Research Study Number       20131756
Principal Investigator       Laura Chow
Phase       II

Look up trial at NIH

Research Study Description

This multicenter, single- arm study will evaluate the efficacy and safety of MPD L3280A in patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer. Patients will receive MPDL3280A 1200 mg intravenously every 3 weeks for a maximum of 16 cycles (or 12 months, whichever occurs first) in the a bsence of unacceptable toxicity or symptomatic deterioration attributed to disea se progression. Patients who complete the initial treatment stage may be eligibl e fro MPDL3280A re-treatment upon subsequent disease progression during the foll ow-up period without intervening systemic anti-cancer therapy.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number       20131756
Contact       Seattle Cancer Care Alliance Intake Office
Telephone       800-804-8824 / 206-288-1024

Lung Cancer; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials